TargeGen Pipeline
Molecule	Targets	Indications	Status
TG101348(oral)	Jak2, Flt3, Ret	MPD, AML, RA and Lymphoma	Phase I/II starts in January, 2008
TG100948(eyedrop)	VEGF, SRC+, PDGF	AMD, DME, RVO	Pre-clinical
TG100115(inhaled aerosol)	PI3K isotypes	Pulmonary Disease	Pre-clinical